Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Conversion of antigen-specific effector/memory T cells into Foxp3-expressing Treg cells by inhibition of CDK8/19.

Akamatsu M, Mikami N, Ohkura N, Kawakami R, Kitagawa Y, Sugimoto A, Hirota K, Nakamura N, Ujihara S, Kurosaki T, Hamaguchi H, Harada H, Xia G, Morita Y, Aramori I, Narumiya S, Sakaguchi S.

Sci Immunol. 2019 Oct 25;4(40). pii: eaaw2707. doi: 10.1126/sciimmunol.aaw2707.

PMID:
31653719
2.

Metabolomic approach to the exploration of biomarkers associated with disease activity in rheumatoid arthritis.

Sasaki C, Hiraishi T, Oku T, Okuma K, Suzumura K, Hashimoto M, Ito H, Aramori I, Hirayama Y.

PLoS One. 2019 Jul 11;14(7):e0219400. doi: 10.1371/journal.pone.0219400. eCollection 2019.

3.

Constitutive Activation of Integrin α9 Augments Self-Directed Hyperplastic and Proinflammatory Properties of Fibroblast-like Synoviocytes of Rheumatoid Arthritis.

Emori T, Hirose J, Ise K, Yomoda JI, Kasahara M, Shinkuma T, Yoshitomi H, Ito H, Hashimoto M, Sugahara S, Fujita H, Yamamoto N, Morita Y, Narumiya S, Aramori I.

J Immunol. 2017 Nov 15;199(10):3427-3436. doi: 10.4049/jimmunol.1700941. Epub 2017 Oct 16.

4.

A sphingosine-1-phosphate receptor type 1 agonist, ASP4058, suppresses intracranial aneurysm through promoting endothelial integrity and blocking macrophage transmigration.

Yamamoto R, Aoki T, Koseki H, Fukuda M, Hirose J, Tsuji K, Takizawa K, Nakamura S, Miyata H, Hamakawa N, Kasuya H, Nozaki K, Hirayama Y, Aramori I, Narumiya S.

Br J Pharmacol. 2017 Jul;174(13):2085-2101. doi: 10.1111/bph.13820. Epub 2017 May 27.

5.

Glucose regulates RMI1 expression through the E2F pathways in adipose cells.

Suwa A, Yoshino M, Kurama T, Shimokawa T, Aramori I.

Endocrine. 2011 Aug;40(1):56-61. doi: 10.1007/s12020-011-9455-4. Epub 2011 Mar 24.

PMID:
21432623
6.

Glucose metabolism activation by SHIP2 inhibitors via up-regulation of GLUT1 gene in L6 myotubes.

Suwa A, Kurama T, Yamamoto T, Sawada A, Shimokawa T, Aramori I.

Eur J Pharmacol. 2010 Sep 10;642(1-3):177-82. doi: 10.1016/j.ejphar.2010.06.002. Epub 2010 Jun 17.

PMID:
20558154
7.

RMI1 deficiency in mice protects from diet and genetic-induced obesity.

Suwa A, Yoshino M, Yamazaki C, Naitou M, Fujikawa R, Matsumoto S, Kurama T, Shimokawa T, Aramori I.

FEBS J. 2010 Feb;277(3):677-86. doi: 10.1111/j.1742-4658.2009.07513.x. Epub 2009 Dec 29.

8.

Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2.

Suwa A, Yamamoto T, Sawada A, Minoura K, Hosogai N, Tahara A, Kurama T, Shimokawa T, Aramori I.

Br J Pharmacol. 2009 Oct;158(3):879-87. doi: 10.1111/j.1476-5381.2009.00358.x. Epub 2009 Aug 19.

9.

Novel method for selecting immunosuppressive histone deacetylase (HDAC) inhibitors with minimal thrombocytopenia.

Matsuoka H, Fujimura T, Unami A, Yamada T, Noto T, Takata Y, Yoshizawa K, Mori H, Aramori I, Mutoh S.

Biol Pharm Bull. 2008 Feb;31(2):305-8.

10.

Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells.

Matsuoka H, Fujimura T, Mori H, Aramori I, Mutoh S.

Int Immunopharmacol. 2007 Nov;7(11):1422-32. Epub 2007 Jul 17.

PMID:
17761346
11.

Mechanisms of HDAC inhibitor-induced thrombocytopenia.

Matsuoka H, Unami A, Fujimura T, Noto T, Takata Y, Yoshizawa K, Mori H, Aramori I, Mutoh S.

Eur J Pharmacol. 2007 Oct 1;571(2-3):88-96. Epub 2007 Jun 26.

PMID:
17628529
12.

Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression.

Matsuoka H, Fujimura T, Hayashi M, Matsuda K, Ishii Y, Aramori I, Mutoh S.

Biochem Pharmacol. 2007 Aug 1;74(3):465-76. Epub 2007 May 6.

PMID:
17559812
13.

Tacrolimus (FK506) limits accumulation of granulocytes and platelets and protects against brain damage after transient focal cerebral ischemia in rat.

Noto T, Furuichi Y, Ishiye M, Matsuoka N, Aramori I, Mutoh S, Yanagihara T.

Biol Pharm Bull. 2007 Feb;30(2):313-7.

14.

Temporal and topographic profiles of tissue hypoxia following transient focal cerebral ischemia in rats.

Noto T, Furuichi Y, Ishiye M, Matsuoka N, Aramori I, Mutoh S, Yanagihara T, Manabe N.

J Vet Med Sci. 2006 Aug;68(8):803-7.

15.

A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.

Dickson L, Aramori I, McCulloch J, Sharkey J, Finlayson K.

Neuropharmacology. 2006 Nov;51(6):1086-98. Epub 2006 Aug 23.

PMID:
16930633
16.

VIP and PACAP receptor pharmacology: a comparison of intracellular signaling pathways.

Dickson L, Aramori I, Sharkey J, Finlayson K.

Ann N Y Acad Sci. 2006 Jul;1070:239-42.

PMID:
16888173
17.

A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.

Fujimura T, Kimura C, Oe T, Takata Y, Sakuma H, Aramori I, Mutoh S.

J Pharmacol Exp Ther. 2006 Aug;318(2):863-71. Epub 2006 May 8.

PMID:
16682454
18.
19.

FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators.

Fujimura T, Sakuma H, Konishi S, Oe T, Hosogai N, Kimura C, Aramori I, Mutoh S.

J Pharmacol Sci. 2005 Dec;99(4):342-52. Epub 2005 Nov 26.

20.

FK1706, a novel non-immunosuppressive immunophilin: neurotrophic activity and mechanism of action.

Price RD, Yamaji T, Yamamoto H, Higashi Y, Hanaoka K, Yamazaki S, Ishiye M, Aramori I, Matsuoka N, Mutoh S, Yanagihara T, Gold BG.

Eur J Pharmacol. 2005 Feb 10;509(1):11-9. Epub 2005 Jan 20.

PMID:
15713424
21.

Neuroprotective effect of tacrolimus (FK506) on ischemic brain damage following permanent focal cerebral ischemia in the rat.

Noto T, Ishiye M, Furuich Y, Keida Y, Katsuta K, Moriguchi A, Matsuoka N, Aramori I, Goto T, Yanagihara T.

Brain Res Mol Brain Res. 2004 Sep 10;128(1):30-8.

PMID:
15337315
22.

Multiple modes of action of tacrolimus (FK506) for neuroprotective action on ischemic damage after transient focal cerebral ischemia in rats.

Furuichi Y, Noto T, Li JY, Oku T, Ishiye M, Moriguchi A, Aramori I, Matsuoka N, Mutoh S, Yanagihara T.

Brain Res. 2004 Jul 16;1014(1-2):120-30.

PMID:
15212998
23.

Discovery of the first non-peptide full agonists for the human bradykinin B(2) receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks.

Sawada Y, Kayakiri H, Abe Y, Mizutani T, Inamura N, Asano M, Hatori C, Aramori I, Oku T, Tanaka H.

J Med Chem. 2004 May 20;47(11):2853-63.

PMID:
15139763
24.

A new class of nonpeptide bradykinin B(2) receptor ligand, incorporating a 4-aminoquinoline framework. Identification of a key pharmacophore to determine species difference and agonist/antagonist profile.

Sawada Y, Kayakiri H, Abe Y, Mizutani T, Inamura N, Asano M, Aramori I, Hatori C, Oku T, Tanaka H.

J Med Chem. 2004 May 6;47(10):2667-77.

PMID:
15115408
25.

A new series of highly potent non-peptide bradykinin B2 receptor antagonists incorporating the 4-heteroarylquinoline framework. Improvement of aqueous solubility and new insights into species difference.

Sawada Y, Kayakiri H, Abe Y, Imai K, Mizutani T, Inamura N, Asano M, Aramori I, Hatori C, Katayama A, Oku T, Tanaka H.

J Med Chem. 2004 Mar 25;47(7):1617-30.

PMID:
15027853
26.

Evaluation of human peroxisome proliferator-activated receptor (PPAR) subtype selectivity of a variety of anti-inflammatory drugs based on a novel assay for PPAR delta(beta).

Kojo H, Fukagawa M, Tajima K, Suzuki A, Fujimura T, Aramori I, Hayashi K, Nishimura S.

J Pharmacol Sci. 2003 Nov;93(3):347-55.

27.

Characterisation of [(125)I]-apamin binding sites in rat brain membranes with HE293 cells transfected with SK channel subtypes.

Finlayson K, McLuckie J, Hern J, Aramori I, Olverman HJ, Kelly JS.

Neuropharmacology. 2001 Sep;41(3):341-50.

PMID:
11522325
28.

Nonpeptide mimic of bradykinin with long-acting properties.

Aramori I, Zenkoh J, Morikawa N, Asano M, Hatori C, Sawai H, Kayakiri H, Satoh S, Inoue T, Abe Y, Sawada Y, Mizutani T, Inamura N, Iwami M, Nakahara K, Kojo H, Oku T, Notsu Y.

Immunopharmacology. 1999 Dec;45(1-3):185-90.

PMID:
10615010
29.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation.

Abe Y, Kayakiri H, Satoh S, Inoue T, Sawada Y, Inamura N, Asano M, Aramori I, Hatori C, Sawai H, Oku T, Tanaka H.

J Med Chem. 1998 Nov 5;41(23):4587-98.

PMID:
9804698
30.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety.

Abe Y, Kayakiri H, Satoh S, Inoue T, Sawada Y, Inamura N, Asano M, Aramori I, Hatori C, Sawai H, Oku T, Tanaka H.

J Med Chem. 1998 Oct 8;41(21):4062-79.

PMID:
9767643
31.

Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor.

Aramori I, Ferguson SS, Bieniasz PD, Zhang J, Cullen B, Cullen MG.

EMBO J. 1997 Aug 1;16(15):4606-16. Erratum in: EMBO J 1997 Oct 1;16(19):6055.

32.

Nonpeptide mimic of bradykinin with long-acting properties at the bradykinin B2 receptor.

Aramori I, Zenkoh J, Morikawa N, Asano M, Hatori C, Sawai H, Kayakiri H, Satoh S, Inoue T, Abe Y, Sawada Y, Mizutani T, Inamura N, Nakahara K, Kojo H, Oku T, Notsu Y.

Mol Pharmacol. 1997 Jul;52(1):16-20.

PMID:
9224807
33.

HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor.

Bieniasz PD, Fridell RA, Aramori I, Ferguson SS, Caron MG, Cullen BR.

EMBO J. 1997 May 15;16(10):2599-609.

34.

Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657.

Aramori I, Zenkoh J, Morikawa N, O'Donnell N, Asano M, Nakamura K, Iwami M, Kojo H, Notsu Y.

Mol Pharmacol. 1997 Feb;51(2):171-6.

PMID:
9203620
35.

Tachykinin antagonists screening from microbial origin.

Hayashi K, Nishikawa M, Aramori I, Kiyoto S, Okuhara M.

J Antibiot (Tokyo). 1996 Jan;49(1):110-2. No abstract available.

36.

Subtype- and species-selectivity of a tachykinin receptor antagonist, FK888, for cloned rat and human tachykinin receptors.

Aramori I, Morikawa N, Zenkoh J, O'Donnell N, Iwami M, Kojo H, Notsu Y, Okuhara M, Ono S, Nakanishi S.

Eur J Pharmacol. 1994 Oct 14;269(2):277-81.

PMID:
7531648
37.

Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells.

Aramori I, Nirei H, Shoubo M, Sogabe K, Nakamura K, Kojo H, Notsu Y, Ono T, Nakanishi S.

Mol Pharmacol. 1993 Feb;43(2):127-31.

PMID:
8429819
38.

Agonist analysis of 2-(carboxycyclopropyl)glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in Chinese hamster ovary cells.

Hayashi Y, Tanabe Y, Aramori I, Masu M, Shimamoto K, Ohfune Y, Nakanishi S.

Br J Pharmacol. 1992 Oct;107(2):539-43.

39.
41.
42.

Alteration of channel activities and gating by mutations of slow ISK potassium channel.

Takumi T, Moriyoshi K, Aramori I, Ishii T, Oiki S, Okada Y, Ohkubo H, Nakanishi S.

J Biol Chem. 1991 Nov 25;266(33):22192-8.

43.

Construction of a 7-aminocephalosporanic acid (7ACA) biosynthetic operon and direct production of 7ACA in Acremonium chrysogenum.

Isogai T, Fukagawa M, Aramori I, Iwami M, Kojo H, Ono T, Ueda Y, Kohsaka M, Imanaka H.

Biotechnology (N Y). 1991 Feb;9(2):188-91.

PMID:
1369453
44.

Cloning and expression of a cDNA encoding an endothelin receptor.

Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S.

Nature. 1990 Dec 20-27;348(6303):730-2.

PMID:
2175396
45.

Role of the cephalosporinase gene in the resistance of the clinically isolated cephem-resistant Escherichia coli.

Aramori I, Kojo H, Nishida M, Goto S, Kuwahara S.

J Antibiot (Tokyo). 1988 Jan;41(1):113-22.

Supplemental Content

Loading ...
Support Center